{"id":"stem-cell","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection at injection site"},{"rate":null,"effect":"Pain or discomfort at injection site"},{"rate":null,"effect":"Immune response or rejection"}]},"_chembl":{"chemblId":"CHEMBL4298054","moleculeType":"Enzyme"},"_dailymed":{"setId":"cf59f639-11f1-4374-9e5a-7a42f0760089","title":"STEM CELLULAR CC CREAM NATURAL GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM ROSY GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM BEACH GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM DESERT GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM WARM GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM SUN-KISSED GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM DEEP GLOW (ZINC OXIDE) LOTION STEM CELLULAR CC CREAM ISLAND GLOW (ZINC OXIDE) LOTION [JUICE BEAUTY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Stem cells, typically derived from bone marrow or other sources, are administered to sites of spinal cord injury or neurological damage where they can differentiate into replacement neurons and supporting glial cells, potentially restoring lost neural function. The mechanism may also involve paracrine effects, including anti-inflammatory signaling and promotion of endogenous repair pathways. This approach is intended to restore motor and sensory function in patients with spinal cord injuries or degenerative neurological conditions.","oneSentence":"Stem cell therapy aims to replace or repair damaged neural tissue by transplanting undifferentiated cells that can differentiate into functional neurons and glial cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:28.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Spinal cord injury"},{"name":"Neurological disorders (specific indications not clearly defined in public literature)"}]},"trialDetails":[{"nctId":"NCT03055013","phase":"PHASE3","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-28","conditions":"Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7","enrollment":819},{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306},{"nctId":"NCT00128960","phase":"","title":"Quality of Life in Patients Who Have Undergone Stem Cell Transplant","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2005-08-11","conditions":"Long Term Psychological Affects on HSCT","enrollment":173},{"nctId":"NCT07495176","phase":"NA","title":"USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias","status":"COMPLETED","sponsor":"Shanghai Children's Hospital","startDate":"2021-02-01","conditions":"Hypospadias","enrollment":82},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT07496372","phase":"PHASE3","title":"Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV)","status":"NOT_YET_RECRUITING","sponsor":"Help Therapeutics","startDate":"2026-04-30","conditions":"Heart Failure","enrollment":80},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT01432847","phase":"","title":"Cell Collection to Study Eye Diseases","status":"RECRUITING","sponsor":"National Eye Institute (NEI)","startDate":"2011-09-07","conditions":"Retinal Disease, AMD, Retinal Degeneration","enrollment":930},{"nctId":"NCT07498218","phase":"PHASE1","title":"Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue","status":"NOT_YET_RECRUITING","sponsor":"Ayu, Inc.","startDate":"2026-03-02","conditions":"Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds","enrollment":24},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT05909202","phase":"NA","title":"A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2024-06-05","conditions":"Neoplasm, Caregivers","enrollment":218},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT00001405","phase":"","title":"Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1994-02-27","conditions":"Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease","enrollment":850},{"nctId":"NCT06321198","phase":"NA","title":"A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-02-10","conditions":"Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)","enrollment":12},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT03000244","phase":"","title":"Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-26","conditions":"Hematopoietic Stem Cell Transplantation, Tissue Donors","enrollment":2000},{"nctId":"NCT06912633","phase":"PHASE2","title":"Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)","status":"RECRUITING","sponsor":"jCyte, Inc","startDate":"2025-06-20","conditions":"Retinitis Pigmentosa","enrollment":60},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT06905834","phase":"PHASE2","title":"Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-05","conditions":"Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)","enrollment":30},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT02669251","phase":"PHASE1, PHASE2","title":"Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-28","conditions":"Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome","enrollment":14},{"nctId":"NCT05665166","phase":"PHASE1, PHASE2","title":"Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-01","conditions":"Mucopolysaccharidosis II","enrollment":5},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT05896163","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT05531786","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-06","conditions":"Graft vs Host Disease","enrollment":50},{"nctId":"NCT07388524","phase":"PHASE3","title":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-09","conditions":"Lung Non-Small Cell Carcinoma","enrollment":336},{"nctId":"NCT07495956","phase":"PHASE1, PHASE2","title":"cfMSC Therapy for Diabetes","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2026-03-16","conditions":"Type II Diabetes Mellitus","enrollment":30},{"nctId":"NCT01303146","phase":"PHASE2","title":"Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Metachromatic Leukodystrophy","enrollment":1},{"nctId":"NCT05139056","phase":"PHASE1","title":"Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2023-05-02","conditions":"Currently Only Enrolling Glioblastoma Patients at First Recurrence","enrollment":36},{"nctId":"NCT03286530","phase":"PHASE2","title":"Ruxolitinib + Allogeneic Stem Cell Transplantation in AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation","enrollment":64},{"nctId":"NCT03111745","phase":"","title":"Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-13","conditions":"Viral Infections","enrollment":730},{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390},{"nctId":"NCT01212055","phase":"","title":"Apheresis of Patients With Immunodeficiency","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-08","conditions":"LAD-1, DOCK8, GATA2 Deficancy","enrollment":7},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT00001529","phase":"","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-03-18","conditions":"Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis","enrollment":500},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT05722210","phase":"","title":"Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Hematopoietic Stem Cell Transplant","enrollment":500},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT07250087","phase":"PHASE1","title":"Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-21","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT05243797","phase":"PHASE3","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2022-09-08","conditions":"Multiple Myeloma","enrollment":1594},{"nctId":"NCT06687837","phase":"PHASE1","title":"Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons","status":"RECRUITING","sponsor":"Jeffrey S. Schweitzer, MD, PhD","startDate":"2025-04-29","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT06209190","phase":"NA","title":"Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-09-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT05246813","phase":"","title":"Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)","status":"RECRUITING","sponsor":"Imelda Hospital, Bonheiden","startDate":"2022-02-11","conditions":"Osteoporosis, Osteoarthritis, Hip, Hip Fractures","enrollment":24},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":"Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT04208529","phase":"PHASE3","title":"A Long-term Follow-up Study in Participants Who Received CTX001","status":"ENROLLING_BY_INVITATION","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-20","conditions":"Beta-Thalassemia, Thalassemia, Sickle Cell Disease","enrollment":160},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT07492966","phase":"","title":"Exosomes Effect on Visual Function in CVI","status":"COMPLETED","sponsor":"Hatice Semrin Timlioglu İper","startDate":"2024-06-30","conditions":"Cortical Visual Impairment, Visual Function","enrollment":32},{"nctId":"NCT07483385","phase":"NA","title":"Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2026-01-13","conditions":"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders","enrollment":45},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07404709","phase":"PHASE1, PHASE2","title":"Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-02-28","conditions":"Sudden Hearing Loss, Extracellular Vesicles","enrollment":9},{"nctId":"NCT07477600","phase":"PHASE1, PHASE2","title":"cfMSC Stem Cell Therapy Targeting COPD","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2026-03-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06798623","phase":"PHASE1","title":"Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-24","conditions":"Anterior Cruciate Ligament Reconstruction","enrollment":15},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT05919511","phase":"","title":"Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-08-01","conditions":"cGVHD","enrollment":1500},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT00092235","phase":"","title":"Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-26","conditions":"Chronic Graft vs. Host Disease","enrollment":650},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT07490392","phase":"","title":"Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantation in Prepubertal Age","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2027-01-01","conditions":"Hematopoietic Stem Cells Transplantation, Pediatrics","enrollment":300},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT07270861","phase":"","title":"Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-15","conditions":"Peripheral T-Cell Lymphoma","enrollment":3000},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07489196","phase":"PHASE2","title":"A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major","status":"NOT_YET_RECRUITING","sponsor":"CorrectSequence Therapeutics Co., Ltd","startDate":"2026-04-05","conditions":"β-thalassemia Major","enrollment":20},{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":"Idiopathic CD4-Positive, T-Lymphocytopenia","enrollment":40},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT07006506","phase":"PHASE2","title":"A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-21","conditions":"Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy","enrollment":46},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT02327884","phase":"","title":"Characterization of Diseases With Salivary Gland Involvement","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2015-04-03","conditions":"Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease","enrollment":1150},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT00106925","phase":"","title":"Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-04-22","conditions":"Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection","enrollment":1000},{"nctId":"NCT06576583","phase":"PHASE2","title":"Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-07-15","conditions":"Patellofemoral Osteoarthritis","enrollment":150},{"nctId":"NCT03949647","phase":"","title":"Collection of Bone Marrow Aspirate From Normal Volunteers","status":"RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2019-05-08","conditions":"Normal Aging","enrollment":2000},{"nctId":"NCT07488728","phase":"NA","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2025-10-01","conditions":"EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir","enrollment":80},{"nctId":"NCT07332338","phase":"","title":"Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","status":"AVAILABLE","sponsor":"StemCyte, Inc.","startDate":"","conditions":"Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome","enrollment":""},{"nctId":"NCT07488663","phase":"NA","title":"MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS","status":"ENROLLING_BY_INVITATION","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2023-04-30","conditions":"Obsessive - Compulsive Disorder","enrollment":60},{"nctId":"NCT04704648","phase":"NA","title":"Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa","status":"RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2023-06-21","conditions":"Ocular Surface Squamous Neoplasia, HPV","enrollment":84},{"nctId":"NCT01890486","phase":"","title":"The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2001-05-21","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":2000},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":"Allogeneic Stem Cell Transplant Recipient","enrollment":209},{"nctId":"NCT05477563","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-08-02","conditions":"Beta-Thalassemia, Thalassemia, Hematologic Diseases","enrollment":26},{"nctId":"NCT02032004","phase":"PHASE3","title":"Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2014-03-03","conditions":"Chronic Heart Failure","enrollment":565},{"nctId":"NCT07487766","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of XytriX in the Treatment of Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"TricelX Inc.","startDate":"2026-05","conditions":"Osteoarthritis","enrollment":50},{"nctId":"NCT07355868","phase":"EARLY_PHASE1","title":"Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy","status":"RECRUITING","sponsor":"Regend Therapeutics","startDate":"2026-03-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":35,"reaction":"MUCOSAL INFLAMMATION"},{"count":28,"reaction":"DRUG TOXICITY"},{"count":25,"reaction":"STEM CELL TRANSPLANT"},{"count":21,"reaction":"NEUTROPENIA"},{"count":20,"reaction":"SEPSIS"},{"count":18,"reaction":"DIARRHOEA"},{"count":18,"reaction":"NAUSEA"},{"count":18,"reaction":"VOMITING"},{"count":17,"reaction":"FEBRILE NEUTROPENIA"},{"count":16,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":241576,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRP","- Edessy Stem cell Score.","- Laparoscopic stem cell transplantation.","- Hormonal Analysis","- Ultrasonic evaluation"],"phase":"marketed","status":"active","brandName":"Stem Cell","genericName":"Stem Cell","companyName":"Neurogen Brain and Spine Institute","companyId":"neurogen-brain-and-spine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stem cell therapy aims to replace or repair damaged neural tissue by transplanting undifferentiated cells that can differentiate into functional neurons and glial cells. Used for Spinal cord injury, Neurological disorders (specific indications not clearly defined in public literature).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}